These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 29242978)

  • 1. Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.
    Tronci E; Francardo V
    J Neural Transm (Vienna); 2018 Aug; 125(8):1137-1144. PubMed ID: 29242978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the selective 5-HT
    Frouni I; Kwan C; Bédard D; Belliveau S; Bourgeois-Cayer É; Gaudette F; Beaudry F; Hamadjida A; Huot P
    Exp Brain Res; 2019 Jan; 237(1):29-36. PubMed ID: 30298296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
    Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
    Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
    Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats.
    Aristieta A; Ruiz-Ortega JA; Morera-Herreras T; Miguelez C; Ugedo L
    Exp Neurol; 2019 Dec; 322():113036. PubMed ID: 31425688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
    Ravenscroft P; Chalon S; Brotchie JM; Crossman AR
    Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
    Thornton E; Hassall MM; Corrigan F; Vink R
    Parkinsonism Relat Disord; 2014 May; 20(5):508-13. PubMed ID: 24637127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
    Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C
    Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
    Wang Y; Wang HS; Wang T; Huang C; Liu J
    J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
    J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
    Smith LM; Parr-Brownlie LC; Duncan EJ; Black MA; Gemmell NJ; Dearden PK; Reynolds JN
    Neuroscience; 2016 Jun; 324():238-51. PubMed ID: 26968766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats.
    Wang T; Cao X; Zhang T; Shi Q; Chen Z; Tang B
    Neurol Sci; 2015 Aug; 36(8):1397-402. PubMed ID: 25787808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoradiographic labelling of metabotropic glutamate type 2/3 receptors in the hemi-parkinsonian rat brain.
    Kim E; Frouni I; Shaqfah J; Bédard D; Huot P
    J Chem Neuroanat; 2024 Jul; 138():102422. PubMed ID: 38657828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat.
    Breger LS; Dunnett SB; Lane EL
    Neurobiol Dis; 2013 Feb; 50():142-50. PubMed ID: 23072976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
    Park HY; Ryu YK; Kim YH; Park TS; Go J; Hwang JH; Choi DH; Rhee M; Lee CH; Kim KS
    Neurobiol Dis; 2016 May; 89():169-79. PubMed ID: 26875664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Alachkar A; Brotchie JM; Jones OT
    J Mol Neurosci; 2012 Jan; 46(1):145-52. PubMed ID: 21562737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.